Steven A Yukl

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Latently-infected CD4+ T cells are enriched for HIV-1 Tat variants with impaired transactivation activity
    Steven Yukl
    University of California, San Francisco UCSF and San Francisco VA Medical Center SFVAMC, 4150 Clement Street, 111W3, San Francisco, CA 94121, USA
    Virology 387:98-108. 2009
  2. ncbi Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy
    Steven A Yukl
    San Francisco VA Medical Center SFVAMC and University of California, San Francisco UCSF, San Francisco, California, USA
    AIDS 24:2451-60. 2010
  3. ncbi Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy
    Steven A Yukl
    San Francisco Veterans Affairs Medical Center, San Francisco, California, USA
    J Infect Dis 202:1553-61. 2010
  4. ncbi Modification of the Abbott RealTime assay for detection of HIV-1 plasma RNA viral loads less than one copy per milliliter
    Steven A Yukl
    San Francisco VA Medical Center, San Francisco, CA 94121, USA
    J Virol Methods 175:261-5. 2011

Detail Information

Publications4

  1. ncbi Latently-infected CD4+ T cells are enriched for HIV-1 Tat variants with impaired transactivation activity
    Steven Yukl
    University of California, San Francisco UCSF and San Francisco VA Medical Center SFVAMC, 4150 Clement Street, 111W3, San Francisco, CA 94121, USA
    Virology 387:98-108. 2009
    ..These findings suggest that impaired activity in the Tat-TAR axis may contribute to the establishment of latent infection in CD4+ T cells...
  2. ncbi Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy
    Steven A Yukl
    San Francisco VA Medical Center SFVAMC and University of California, San Francisco UCSF, San Francisco, California, USA
    AIDS 24:2451-60. 2010
    ..To determine whether raltegravir-containing antiretroviral therapy (ART) intensification reduces HIV levels in the gut...
  3. ncbi Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy
    Steven A Yukl
    San Francisco Veterans Affairs Medical Center, San Francisco, California, USA
    J Infect Dis 202:1553-61. 2010
    ..The gut is a major reservoir for human immunodeficiency virus (HIV) in patients receiving antiretroviral therapy (ART). We hypothesized that distinct immune environments within the gut may support varying levels of HIV...
  4. ncbi Modification of the Abbott RealTime assay for detection of HIV-1 plasma RNA viral loads less than one copy per milliliter
    Steven A Yukl
    San Francisco VA Medical Center, San Francisco, CA 94121, USA
    J Virol Methods 175:261-5. 2011
    ..77 copy/ml; 95% CI 0.86-4.68 copy/ml). The measured viral load correlated inversely (r = -0.78; p = 0.028) with the total duration of viral suppression (viral load<40 copies/ml)...